Method for assessing disease states by profile analysis of isolated circulating endothelial cells

• US 7,901,950 B2
• Filed: 02/02/2007
• Issued: 03/08/2011
• Est. Priority Date: 08/12/2005
• Status: Active Grant

• Current Assignee: Menarini Silicon Biosystems S.P.A
• Original Assignee: Veridex LLC (Johnson & Johnson)
• Inventors: Connelly, Mark Carle, Doyle, Gerald V., Rao, Galla Chandra, Terstappen, Leon W. M. M.
• Primary Examiner(s): GABEL, GAILENE
• Application Number:
  US11/701,763
• Publication Number:
  US 20070154960A1
• Time in Patent Office: 1,495 Days
• Field of Search: 435/1.1, 435/2, 435/7.2, 435/7.23, 435/7.24, 435/372, 435/287.2, 435/40.51, 436/526, 436/536, 436/538, 436/10, 436/17, 436/18, 436/63, 436/64, 436/172, 436174-177, 436/518, 436/523, 422/68.1, 422/73, 422/82.05, 422/101
• US Class Current: 436/526
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: Y10T 436/101666 Particle count or volume standard or control [e.g., platelet count standards, etc.]
• CPC Class Codes: Y10T 436/107497 Preparation composition [e.g., lysing or precipitation, etc.]
• CPC Class Codes: Y10T 436/108331 Preservative, buffer, anticoagulant or diluent
• CPC Class Codes: Y10T 436/2525 Stabilizing or preserving
• CPC Class Codes: Y10T 436/25375 Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]

Abstract

Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.

Claims

1. A method for assessing changes in cardiovascular homeostasis, comprising:

a. obtaining a whole blood from a test subject suspected of having a cardiovascular disorder, said whole blood specimen comprising a mixed cell population suspected of having target cells selected from the group consisting of endothelial cells, epithelial cells, and combinations thereof;

b. contacting said whole blood specimen with a preservative capable of stabilizing said mixed population;

c. mixing said whole blood specimen from step b with colloidal magnetic particles between 90 to 150 nm in size coated with stabilizing material and adapted to permit less than 0.3% non-specific binding and coupled to a monoclonal antibody which binds specifically to said target cells so as to capture the target cells, to the substantial exclusion of non-target cells;

d. subjecting the specimen-magnetic particle mixture to a high gradient magnetic field to produce a separated cell fraction enriched in magnetic particle-bound target cells; and

e. enumerating the target cells that are nucleated, CD146 positive, CD105 positive, and CD45 negative using multiparameter image cytometry wherein a change in the number of said target cells in comparison to predetermined normal control values from subjects having normal cardiovascular homeostasis provides indication of a change in cardiovascular homeostasis.

2. The method of claim 1, wherein said preservative contains an anti-coagulating agent and a stabilizing agent.

3. The method of claim 1, wherein said monoclonal antibody specifically binds cell surface antigens selected from the group consisting of CD146, CD105, and combinations thereof.

4. The method of claim 1, wherein said enumerating is indicative of changes in stenosis, organ transplant status, heart disease, or combinations thereof.

5. The method of claim 1, wherein said target cells are determined to be nucleated using a nuclear stain.

6. The method of claim 5, wherein the nuclear stain is DAPI.